67
porcine genome engineering for xenotransplantation.[2020][adv drug deliv rev].pdf
porcine genome engineering for xenotransplantation.[2020][adv drug deliv rev]
66
rationally designed dna-based nanocarriers.[2019][adv drug deliv rev][10.1016j.addr.2019.02.003].pdf
rationally designed dna-based nanocarriers.[2019][adv drug deliv rev][10.1016j.addr.2019.02.003]
58
applying nanomedicine in maladaptive inflammation and angiogenesis.[2017][adv drug deliv rev][10.1016j.addr.2017.05.009].pdf
applying nanomedicine in maladaptive inflammation and angiogenesis.[2017][adv drug deliv rev][10.1016j.addr.2017.05.009]
56
nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs.[2017][adv drug deliv rev][10.1016j.addr.2017.06..pdf
nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs.[2017][adv drug deliv rev][10.1016j.addr.2017.06.
70
peptide-modified nanomedicines for targeting cells at the tumor microenvironment.[2017][adv drug deliv rev][10.1016j.addr.2017.05.006].pdf
peptide-modified nanomedicines for targeting cells at the tumor microenvironment.[2017][adv drug deliv rev][10.1016j.addr.2017.05.006]
73
pharmaceutical solvates, hydrates and amorphous forms.[2017][adv drug deliv rev][10.1016j.addr.2017.03.002].pdf
pharmaceutical solvates, hydrates and amorphous forms.[2017][adv drug deliv rev][10.1016j.addr.2017.03.002]
53
nanoformulations for combination or cascade anticancer therapy.[2017][adv drug deliv rev][10.1016j.addr.2017.06.003].pdf
nanoformulations for combination or cascade anticancer therapy.[2017][adv drug deliv rev][10.1016j.addr.2017.06.003]
117
nanoparticles for drug delivery to the anterior segment of the eye.[2017][adv drug deliv rev][10.1016j.addr.2017.04.001].pdf
nanoparticles for drug delivery to the anterior segment of the eye.[2017][adv drug deliv rev][10.1016j.addr.2017.04.001]
61
precision monitoring of immunotherapies in solid organ and hematopoietic stem cell transplantation.[2017][adv drug deliv rev][10.1016j.addr.2017.06.pdf
precision monitoring of immunotherapies in solid organ and hematopoietic stem cell transplantation.[2017][adv drug deliv rev][10.1016j.addr.2017.06
57
emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors.[2017][adv drug deliv rev][10.1016j.addr.2017.06.pdf
EmergingStrategies DeliveringAntiangiogenic Therapies PrimaryandMetastatic Brain TumorsVasileios Ask

向豆丁求助:有没有Deliv?

如要投诉违规内容,请联系我们按需举报;如要提出意见建议,请到社区论坛发帖反馈。
意见反馈
扫二维码
获取二维码用手机继续访问
微信推广

扫码关注微信公众号 享多重好礼

  • 豆丁网(微信号:doudingwang)
  • 豆丁网
  • 豆丁网官方订阅号
  • 豆丁建筑(微信号:doudingjz)
  • 豆丁建筑
  • 建筑圈学习交流平台
  • 豆丁文档(微信号:docin2013)
  • 豆丁文档
  • 豆丁网官方服务号
  • 不止于书(微信号:buzhiyushu)
  • 不止于书
  • 阅读遇见更好的自己
在线客服